|1.||Boylan, John F: 5 articles (03/2015 - 10/2009)|
|2.||Clarke, Blaise A: 3 articles (05/2015 - 10/2013)|
|3.||Ivy, S Percy: 3 articles (05/2015 - 10/2013)|
|4.||Oza, Amit M: 3 articles (05/2015 - 10/2013)|
|5.||Wang, Lisa: 3 articles (05/2015 - 10/2013)|
|6.||Hirte, Hal W: 2 articles (05/2015 - 04/2014)|
|7.||Reedijk, Michael: 2 articles (05/2015 - 04/2014)|
|8.||Diaz-Padilla, Ivan: 2 articles (05/2015 - 10/2013)|
|9.||Razak, Albiruni R A: 2 articles (02/2015 - 04/2014)|
|10.||Dasari, Arvind: 2 articles (08/2014 - 07/2012)|
04/01/2013 - "Overexpression of wild-type PTEN in PTEN-null and -mutant cell lines, and studies with isogenic breast cell lines that differ only in PTEN status, confirmed the importance of PTEN expression for conferring tumor cell susceptibility to RO4929097. "
05/01/2015 - "Secondary objectives included assessment of the safety of RO4929097 and exploration of molecular correlates of outcome in archival tumor tissue and serum. "
10/01/2009 - "RO4929097 does not block tumor cell proliferation or induce apoptosis but instead produces a less transformed, flattened, slower-growing phenotype. "
10/01/2009 - "RO4929097 inhibits Notch processing in tumor cells as measured by the reduction of intracellular Notch expression by Western blot. "
05/01/2012 - "RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts."
|3.||Melanoma (Melanoma, Malignant)
02/01/2015 - "RO4929097 showed minimal clinical activity against metastatic melanoma in this phase 2 trial, possibly because of inadequate exposure to therapeutic drug levels. "
02/01/2015 - "Although Notch inhibition remains a compelling target in melanoma, the results do not support further investigation of RO4929097 with this dose and schedule."
01/01/2011 - "In human primary melanoma cell lines, RO4929097 decreased the levels of NOTCH transcriptional target HES1. "
02/01/2015 - "Chemotherapy-naive patients with metastatic melanoma of cutaneous or unknown origin were treated orally with RO4929097 at a dose of 20 mg daily 3 consecutive days per week. "
01/01/2011 - "The effects of RO4929097 on the oncogenic and stem cell properties of a panel of melanoma cell lines were tested both in vitro and in vivo, using xenograft models. "
|4.||Inflammatory Breast Neoplasms
|5.||Colorectal Neoplasms (Colorectal Cancer)
05/01/2012 - "In this study of RO4929097 in patients with refractory metastatic colorectal cancer, no radiographic responses were seen and time to progression was short, which suggests that RO4929097 at the study dose and schedule has minimal single agent activity in this malignancy."
05/01/2012 - "A phase II study of RO4929097 in metastatic colorectal cancer."
05/01/2012 - "We tested the activity of RO4929097 in patients with metastatic, refractory colorectal cancer. "
|1.||Amyloid Precursor Protein Secretases (beta-Secretase)
|3.||Interleukin-8 (Interleukin 8)
|4.||Interleukin-6 (Interleukin 6)
|8.||Biological Markers (Surrogate Marker)
|9.||Etoposide (VP 16)
|10.||Carrier Proteins (Binding Protein)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)